German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER plus ) node negative (N0) and node positive (N plus ) early breast cancer

被引：3
|
作者：
Blohmer, J. -U. [1 ]
Kuehn, T. [2 ]
Rezai, M. [3 ]
Kuemmel, S. [4 ]
Warm, M. [5 ]
Eggemann, H. [6 ]
Friedrichs, K. [7 ]
Eiermann, W. [8 ]
机构：
[1] St Gertraudenkrankenhaus, Berlin, Germany
[2] Klinikum, Esslingen, Germany
[3] Luisenkrankenhaus, Dusseldorf, Germany
[4] Kliniken Essen Mitte, Essen, Germany
[5] Krankenhaus Holweide, Cologne, Germany
[6] Univ Krankenhaus, Magdeburg, Germany
[7] Mammazentrum, Hamburg, Germany
[8] Rotkreuzkrankenhaus, Munich, Germany
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
10.1016/S0960-9776(11)70147-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR plus ), Node Negative (NO) and Node Positive (N plus ) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic (MDC).
    de Boer, R. H.
    Baker, C.
    Speakman, D.
    Mann, B.
    CANCER RESEARCH, 2011, 71
  • [2] Impact of the Oncotype DX® Recurrence Score® Assay on therapy recommendations for ER-positive (ER+), node negative (N0) and node positive (N+) early breast cancer - Results of an interim analysis of the German decision impact study
    Blohmer, J. -U.
    Rezai, M.
    Kuemmel, S.
    Kuehn, T.
    Warm, M.
    Friedrichs, K.
    Schneeweiss, A.
    Markmann, S.
    Eggemann, H.
    Hilfrich, J.
    Jackisch, C.
    Witzel, I
    Eidtmann, H.
    Kaufmann, M.
    Eiermann, W.
    ONKOLOGIE, 2011, 34 : 119 - 120
  • [3] Recurrence Score (RS) and Treatment Decisions in Node-positive (N plus ), Estrogen Receptor-positive (ER plus ) Breast Cancer Patients in Israel
    Stemmer, S. M.
    Lieberman, N.
    Efrat, N.
    Geffen, D. B.
    Steiner, M.
    Soussan-Gutman, L.
    Merling, S.
    Rizel, S.
    Klang, S. H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [4] A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER plus ) node negative (pN0) breast cancer in academic Canadian centers
    Davidson, James Ashley
    Cromwell, Ian
    Ellard, Susan
    Lohrisch, Caroline A.
    Gelmon, Karen A.
    Shenkier, Tamara Nina
    Villa, Diego
    Lim, Howard John
    Sun, Sophie
    Taylor, Sara Kristina
    Taylor, Marianne
    Czerkawski, Barbara
    Hayes, Malcolm
    Ionescu, Diana
    Pope, Janice
    Berube, Jayne
    Yoshizawa, Carl N.
    Chao, Calvin
    Peacock, Stuart
    Chia, Stephen K. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer - Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease.
    Rezai, M.
    Eiermann, W.
    Kuemmel, S.
    Kuehn, T.
    Warm, M.
    Friedrichs, K.
    Schneeweiss, A.
    Markmann, S.
    Eggemann, H.
    Hilfrich, J.
    Jackisch, C.
    Witzel, I.
    Eidtmann, H.
    Kaufmann, M.
    Blohmer, J. U.
    CANCER RESEARCH, 2011, 71
  • [6] Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution
    Gasol Cudos, A.
    Morales Murillo, S.
    Panades Siurana, M. J.
    Vilardell Villellas, F.
    Canosa Morales, C.
    Mele Olive, J.
    Iglesias Martinez, E.
    Salud Salvia, A.
    BREAST, 2017, 32 : S92 - S93
  • [7] Utilizing the Oncotype DX Recurrence Score in the Adjuvant Treatment Management of Node-Positive, Early-Stage Breast Cancer Patients
    Nguyen, M. T.
    Chen, Z.
    D'Alfonso, T.
    Stessin, A.
    Nagar, H.
    Hayes, M.
    Shin, S. J.
    LABORATORY INVESTIGATION, 2013, 93 : 59A - 59A
  • [8] Utilizing the Oncotype DX Recurrence Score in the Adjuvant Treatment Management of Node-Positive, Early-Stage Breast Cancer Patients
    Nguyen, M. T.
    Chen, Z.
    D'Alfonso, T.
    Stessin, A.
    Nagar, H.
    Hayes, M.
    Shin, S. J.
    MODERN PATHOLOGY, 2013, 26 : 59A - 59A
  • [9] The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland
    Keegan, N. M.
    Milewski, M.
    Kelly, C. M.
    Murphy, V.
    Chao, C.
    Walsh, J.
    Kennedy, M. J.
    O'Connor, M.
    Murphy, C.
    O'Reilly, S.
    Keane, M.
    Duffy, K.
    Hennessy, B.
    Morris, P. G.
    CANCER RESEARCH, 2017, 77
  • [10] The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor positive (ER plus ), lymph node positive (LN plus ) breast cancer (BC) in Ireland: A national, multi-centre, prospective study
    Mullally, William J.
    Bracken-Clarke, Dara
    Padmore, Andrew
    O'Reilly, Seamus
    O'Mahony, Deirdre
    Walshe, Janice
    Kennedy, John
    Gupta, Rajnish
    Kelly, Cathy
    O'Connor, Miriam
    Duffy, Karen
    Keane, Maccon
    Hennessy, Bryan T.
    Morris, Patrick G.
    CANCER RESEARCH, 2020, 80 (04)
12345